Heparanase interacting BCLAF1 to promote the development and drug resistance of ICC through the PERK/eIF2α pathway

• Published in: Cancer gene therapy 2024-06, Vol.31 (6), p.904-916
• Main Authors: Yuan, Fengyan, Zhou, Huiqin, Liu, Chongyang, Wang, Yi, Quan, Jing, Liu, Jie, Li, Hao, von Itzstein, Mark, Yu, Xing
• Format: Article
• Language: English
• Subjects: 13/109; 13/31; 13/51; 38/91; 631/67/395; 64/60; 692/308/53; 82/1; 82/58; Animals; Apoptosis; Bcl-2 protein; Bile Duct Neoplasms - drug therapy; Bile Duct Neoplasms - genetics; Bile Duct Neoplasms - metabolism; Bile Duct Neoplasms - pathology; Biomedical and Life Sciences; Biomedicine; Cancer therapies; Cell Line, Tumor; Cell Proliferation; Chemoresistance; Chemotherapy; Cholangiocarcinoma; Cholangiocarcinoma - drug therapy; Cholangiocarcinoma - genetics; Cholangiocarcinoma - metabolism; Cholangiocarcinoma - pathology; Drug resistance; Drug Resistance, Neoplasm; eIF-2 Kinase - genetics; eIF-2 Kinase - metabolism; Endoplasmic reticulum; Endoplasmic Reticulum Stress - drug effects; Eukaryotic Initiation Factor-2 - metabolism; Female; Gemcitabine; Gene Expression; Gene Therapy; Glucuronidase - genetics; Glucuronidase - metabolism; Humans; Male; Medical prognosis; Metastases; Metastasis; Mice; Mice, Nude; Signal Transduction; Tumors; Xenograft Model Antitumor Assays
• ISSN: 0929-1903; 1476-5500; 1476-5500
• DOI: 10.1038/s41417-024-00754-y

Intrahepatic cholangiocarcinoma (ICC) is a primary epithelial carcinoma known for its aggressive nature, high metastatic potential, frequent recurrence, and poor prognosis. Heparanase (HPSE) is the only known endogenous β -glucuronidase in mammals. In addition to its well-established enzymatic roles, HPSE critically exerts non-catalytic function in tumor biology. This study herein aimed to investigate the non-enzymatic roles of HPSE as well as relevant regulatory mechanisms in ICC. Our results demonstrated that HPSE was highly expressed in ICC and promoted the proliferation of ICC cells, with elevated HPSE levels implicating a poor overall survival of ICC patients. Notably, HPSE interacted with Bcl-2-associated factor 1 (BCLAF1) to upregulate the expression of Bcl-2, which subsequently activated the PERK/eIF2α-mediated endoplasmic reticulum (ER) stress pathway to promote anti-apoptotic effect of ICC. Moreover, our in vivo experiments revealed that concomitant administration of gemcitabine and the Bcl-2 inhibitor navitoclax enhanced the sensitivity of ICC cells with highly expressed HPSE to chemotherapy. In summary, our findings revealed that HPSE promoted the development and drug resistance of ICC via its non-enzymatic function. Bcl-2 may be considered as an effective target with therapeutic potential to overcome ICC chemotherapy resistance induced by HPSE, presenting valuable insights into the development of novel therapeutic strategies against ICC.